Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Can the Gut Microbiome be the Answer to Personalized Healthcare?

Gut health awareness has been playing a pivotal role in the improvement of health as more and more people begin to prioritize the state of microbiome in their bodies. Health experts say that the gut provides an answer to someone’s health, particularly, their digestion and mood, according to Hopkins Medicine. Additionally, the body’s immune system…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Promoted content from Highway to Health on MarketScale.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

Gut health awareness has been playing a pivotal role in the improvement of health as more and more people begin to prioritize the state of microbiome in their bodies. Health experts say that the gut provides an answer to someone’s health, particularly, their digestion and mood, according to Hopkins Medicine. Additionally, the body’s immune system is interconnected with the gut, as up to 80 percent of immune cells are located in the gut. The growing focus on this unique area of health is why concepts like precise healthcare are becoming more common. It is also why the microbiome is prioritized in the idea that led to the creation of Day Two — a comprehensive and personalized microbiome-based health plan.

So, how does emphasizing precision in healthcare benefit patients and how is microbiome the key to that?

The Chief Medical Officer of Day Two, Aamir Rehman, discussed this on the latest episode of “Highway to Health” with host David Kemp. Rehman also delved into how Day Two the step towards unique care that is specific to a person’s needs.

Kemp and Rehman further discussed …

  1. How Day Two functions and provides health professionals with individualized information based on a person’s microbiome
  2. How the gut’s microbiome is used to determine a specific health plan
  3. Why precise healthcare can command and provide the best solutions for any given condition and healthy lifestyle

“If you can create personalization and precision for people, that is probably one of the most important things that allows them greater control over their health. Because one, they have confidence that the science that is precise to them and hopefully it will make a difference, and then two, they can figure out how best to comply with it,” said Rehman.

Amir Rehman is a Physician Executive and the Chief Medical Officer the Day Two. He is also the Executive Clinical and Commercial Advisor at Clinical Innovation and Strategy Advisors and has held senior positions in healthcare organizations for more than a decade.

Highway to Health

Part of this channel

Highway to Health

Healthcare innovation conversations for executives and technology buyers.

Visit the channel

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly has broken ground on a $6.5 billion manufacturing facility in Houston, slated for completion around 2030. While attention has focused on scaling production of Foundayo, its oral GLP-1 treatment, the project also reflects broader U.S. efforts to rebuild domestic pharmaceutical manufacturing and highlights the supply chain challenge of forecasting demand and building capacity years in advance.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain, making it difficult to commit billions to manufacturing capacity years before demand and required output are clear.
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

NextGen Invent’s Deepak Mittal argues for scoped healthcare AI pilots with early governance

NextGen Invent’s Deepak Mittal argues that healthcare AI pilots can begin with a reliable data subset and early governance. His performance figures are vendor claims, not independently verified results.

  • 01Deepak Mittal advocates starting with a defined problem and suitable data rather than waiting for perfect organization-wide data.
  • 02Some performance figures cited in the interview (for example, preparation time and model counts) are company-reported and not independently verified in this article.
  • 03NIST’s voluntary AI Risk Management Framework provides an independent structure for governance and risk evaluation.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512